International Journal of Drug Policy

IntroductionMaternal mental health conditions, comprising maternal suicide and drug overdose, are currently the leading cause of maternal mortality in the United States. However, the relationship between suicidality and drug use behavior in the perinatal period is not well understood. We examined the association between suicidality and drug use behavior among perinatal individuals. Given the racial disparities in both drug use and suicide rates in the U.S., we also examined any differences in suicidality and drug use behavior by race. MethodsParticipants were recruited from a High-Risk Obstetric & Gynecological Clinic in the Midwestern U.S that specializes in providing obstetric care to perinatal individuals who have histories or current use of opioids and other illicit drugs. Participants (N = 66) were a sub-sample of a larger cohort enrolled in an mHealth intervention to support recovery from opioid and stimulant use disorders. We performed chi-square tests and t-tests to examine any significant associations between lifetime suicidality and drug use behavior during the perinatal period. ResultsThe final analytic sample included participants who had responded to the suicidality survey questions (n=43). Nearly 40% (n=16) of our sample endorsed a lifetime history of suicidal thoughts and behaviors (SITB). Of those, 87% (n=15) reported a previous suicide attempt. SITB was significantly associated with cravings for opioids during the perinatal period (p = .01) as well as comorbidities with perinatal anxiety symptoms? ( p < .05), depression symptoms? (p < .05), and bipolar disorder (p < .05). A higher proportion of recent cannabis use was found among mothers with SITB, compared to those without SITB (p=0.04). Mothers with SITB also had a strong positive correlation between preconception and postnatal nicotine use compared to mothers without SITB (p < .01). Finally, while white mothers endorsed more lifetime overdoses (p= 0.01), Black mothers endorsed higher cravings for opioids during pregnancy (p = 0.03). ConclusionsA history of SITB is a distinct risk factor for both illicit and recreational drug use behavior in the perinatal period, and frequently co-occurs with other perinatal mental health conditions. Further research is needed to better understand the directionality of this relationship and the complex interplay between high risk drug use behavior and suicidality.

BackgroundCannabis use is highly prevalent among people who use unregulated drugs. While daily cannabis use has been hypothesized to provide protective effects through substitution or tolerance mechanisms, the relationship between cannabis use frequency and overdose risk remains poorly understood, particularly for infrequent users. MethodsWe conducted a secondary analysis of cross-sectional interview data from people who use unregulated drugs in Vancouver, British Columbia, collected during the fentanyl crisis (November 2019-July 2021; n=657). Binary logistic regression examined associations between self-reported cannabis use frequency (five categories: less than monthly, 1-3 times per month, weekly, more than weekly and daily) and non-fatal overdose in the preceding six months. Daily use served as the reference category. Models adjusted for age, gender, ethnicity, homelessness, mental health, HIV status, incarceration and daily use of alcohol, opioids, fentanyl, cocaine and stimulants. ResultsAmong 657 participants, 95 (14.5%) reported non-fatal overdose in the past six months. In adjusted models with daily cannabis use as the reference, infrequent cannabis use was associated with significantly increased odds of overdose: use 1-3 times per month (aOR=3.17, 95% CI: 1.50-6.69, p=.002) and more than weekly use (aOR=3.13, 95% CI: 1.70-5.76, p<.001) showed approximately three-fold increased odds compared to daily use. Less frequent use showed non-significant trends in the same direction (less than monthly: aOR=1.73, 95% CI: 0.89-3.37, p=.109; weekly: aOR=1.44, 95% CI: 0.59-3.51, p=.421). Sensitivity analysis restricted to participants with daily stimulant or fentanyl use (n=148) revealed even stronger associations. ConclusionsInfrequent cannabis use was associated with substantially increased overdose risk compared to daily use. This frequency-dependent relationship, with infrequent users at highest risk, likely reflects tolerance differences: infrequent users lack tolerance to synergistic cannabis-opioid effects. These findings were completely obscured in preliminary analyses that dichotomized cannabis use as daily versus less-than-daily, demonstrating how analytical choices can mask critical public health insights. Current harm reduction approaches, including cannabis distribution programs, should incorporate frequency-dependent risk communication and develop strategies to protect infrequent users who may be at heightened overdose risk.

IntroductionRecreational and medical cannabis use (CU) information is often available within the electronic health record (EHR) in a format that is impractical for health care provider use. Transformation of free-text EHR documentation in notes to discrete elements is possible using natural language processing (NLP) and has the potential to characterize CU efficiently. The objective of this study was to develop an NLP algorithm to identify documentation of CU within EHR unstructured clinical notes. MethodsWe identified EHR notes with cannabis-related terminologies through a keyword search among all Geisinger patients with at least one encounter between 1/1/2013 and 6/30/2022. We trained four NLP models to classify notes into six categories based on time, context, and reliability of CU documentation identified through manual annotation. We compared the demographic characteristics of patients with positive classification for CU using the best-performing model to those of the overall population. ResultsOf the over 1.7 million eligible patients, 150,726 (8.6%) were flagged as cannabis users. The Bio-ClinicalBERT, a transformer-based NLP model, achieved close to human performance in classifying CU (weighted Precision=91.4, Recall=93.3, F-score=92.4). Cannabis users had higher BMI and were at least nine-fold more likely to use tobacco, alcohol, and illicit substances. ConclusionOur study evaluated the prevalence of CU documentation across the entire corpus of EHR notes data without population segmentation. The NLP methodologies used achieved performance close to that of human annotation and laid the foundation for identifying and classifying CU within unstructured data sources, with future applications in research and patient care. Plain Language SummaryMarijuana, also known as cannabis, may impact the health of patients, yet it is not routinely captured in medical records, and when documented, it is often found in unstructured formats (e.g., progress notes) rather than in discrete fields. Incomplete and unstructured capture limits many functional capabilities within the EHR that enhance patient care (e.g., drug interactions, notifications) and limit researchers from identifying patients routinely exposed to marijuana use. The transformation of free-text documentation of cannabis use (CU) into discrete elements can be performed using natural language processing (NLP). The objective of this study was to develop an NLP model to identify CU in unstructured clinical notes in the EHR. We examined the EHRs of Geisinger patients in Pennsylvania over a 10-year period. Among 1.7 million patients, 9% were identified as CU. One of the NLP models tested, Bio-ClinicalBERT, achieved the highest performance. Cannabis users had a higher BMI and were ten-fold more likely to be tobacco users, ten-fold more likely to use alcohol, and nine-fold more likely to use illicit substances. NLP can be used to better understand the risks and benefits of CU at a population level and may improve patient identification to assist clinical decision-making. Future CU epidemiological research should continue to explore other avenues to automate and improve CU documentation by leveraging rapidly evolving technologies, such as artificial intelligence-driven tools.

Tobacco use disorder (TUD) remains a leading cause of preventable mortality, and existing pharmacotherapies yield 12-month abstinence rates below 30%. As cannabis legalization expands, approximately 18-22% of people who use tobacco report concurrent cannabis use, yet the impact of co-use on cessation outcomes and the therapeutic potential of endocannabinoid system (ECS) modulation remain unclear. We conducted a translational systematic review and meta-analysis following PRISMA 2020 guidelines, searching Ovid MEDLINE, Embase, APA PsycInfo, and Web of Science through January 2026 (PROSPERO: CRD420250652724). Three study categories were eligible: observational studies of cannabis co-use and cessation outcomes; preclinical studies of cannabinoid modulators on nicotine-related behaviors; and human experimental studies of ECS-targeted interventions. Of 4,869 records screened, 52 studies met inclusion criteria. Meta-analysis of 18 observational studies (N=229,630) revealed that cannabis use was associated with 35% lower odds of achieving tobacco smoking cessation (OR=0.65; 95% CI: 0.55-0.78; p<0.0001; I{superscript 2}=88.1%). Preclinical evidence (15 studies) demonstrated that CB1 receptor antagonists robustly reduced nicotine self-administration and reinstatement, while cannabidiol (CBD) attenuated both nicotine intake and withdrawal without affecting food reinforcement. Clinical translation of CB1 receptor inverse agonists failed due to psychiatric adverse effects, but CBD showed promise by reducing cigarette consumption by 40%, reversing attentional bias to smoking cues, and alleviating withdrawal severity. These findings distinguish naturalistic cannabis exposure from potentially beneficial targeted ECS modulation, and support CBD as a promising candidate for adequately powered tobacco cessation trials.

Background and AimsAlcohol use disorder (AUD) remains a major public health concern, with persistent disparities in access to evidence-based treatment. This study aimed to examine associations between perceived discrimination in healthcare settings (PDHS), patient-clinician communication (PCC), and receipt of treatment for AUD, and compared these with sociodemographic and insurance-related factors. DesignCross-sectional analysis using structural equation modeling (SEM), logistic and multinomial logistic regression, and machine learning approaches including SHapley Additive exPlanations (SHAP). SettingUnited States, using data from the National Institutes of Health All of Us Research Program. ParticipantsA total of 5,287 adults with AUD (mean age 61 years; 57% men), including 71.6% non-Hispanic White, 12.2% Black, and 8.6% Hispanic participants. Insurance coverage included 52% government (Medicaid/Medicare), 37% private, and 21% military with 19% reporting more than one type. MeasurementsPrimary outcomes were receipt of Food and Drug Administration-approved pharmacotherapy and/or psychotherapy for AUD, examined as binary and multinomial outcomes. The primary exposure was PDHS, measured using a 7-item scale (range 7-35), with higher scores indicating more frequent discrimination. PCC, assessed using a 2-item scale (range 2-8) with higher scores indicating poorer communication, was examined as a potential mediator. Models were adjusted for age group, sex at birth, race/ethnicity, insurance type (government, private, military), household income, and Alcohol Use Disorders Identification Test-Consumption (AUDIT-C) scores (range 0-12). FindingsPDHS was associated with poorer PCC ({beta} = 0.209, p < 0.001), although communication was not independently associated with treatment receipt. The indirect pathway from discrimination to treatment via communication was not supported. Military insurance was the strongest predictor of treatment receipt, with 6-7 times higher odds compared with other insurance types. Higher AUDIT-C scores and greater PDHS were also associated with increased likelihood of treatment. In analyses restricted to civilian participants, PDHS showed a stronger association with treatment receipt, while PCC demonstrated more modest effects. Machine learning models identified PDHS, AUDIT-C, and PCC as strong contributors, with the impact of poor communication most pronounced among individuals with lower income. ConclusionsAccess to treatment for alcohol use disorder is most strongly associated with insurance coverage, particularly military insurance. PDHS and PCC also contribute to treatment engagement, with differential effects across socioeconomic groups. These findings highlight the importance of addressing structural and interpersonal barriers to improve equitable access to evidence-based AUD treatment.

BackgroundPsychotherapy is proven efficacious for the treatment of alcohol use disorder (AUD). However, the patient-perceived importance of its effect is not fully appreciated in the evidence base. The smallest worthwhile difference (SWD) represents the smallest beneficial effect of an intervention that patients deem worthwhile in exchange for the harms, expenses, and inconveniences associated with the intervention, and facilitates the interpretation of patient perceived worthiness of an intervention. MethodsThe proposed study will estimate the SWD of NIAAA recommended psychotherapies for AUD treatment with English-speaking American respondents aged 18 and older. Primary participants will be recruited using the Prolific research crowdsourcing site. The SWD will be estimated using the Benefit-Harm Trade-off Method, presenting survey respondents with variable, hypothetical magnitudes of psychotherapy outcomes to find the smallest acceptable effect over a natural remission alternative. The overall average SWD, and subgroup distributions by participant AUD treatment experiences and AUD symptomology will be described. Secondary findings will estimate the smallest recommendable risk difference for AUD psychotherapy from providers and criminal justice professionals. Expected ResultsWe expect to find an estimate of the SWD for AUD psychotherapy. Further, we expect that the SWD will vary between clinical subgroups based on AUD symptomology and treatment experiences. We expect differences in SWDs between the general population and those of providers and criminal justice professionals. Findings from this project will inform the treatment decision process about psychotherapy during the clinical consultation for people with AUD.

BackgroundSubstance use disorders (SUD) are associated with a high global burden of disease, with 5.4% of all disability-adjusted life years lost due to alcohol and illicit drugs. Highly prevalent multimorbidity includes polysubstance use, mental health conditions, and other non-communicable and infectious diseases. Where traditional treatments are insufficient alone, music therapy (MT) is highly engaging and improves motivation and reduces craving; however, its long-term effects are unknown. The present study aims to examine long-term effects of active music groups (AMG) and music listening groups (MLG) versus treatment as usual (TAU) on addiction severity, recovery, and other outcomes in people with SUD Immediate and short-term effects, as well as mechanisms of these interventions, will also be examined. MethodsIn individuals with SUD across a wide range of age, gender, socioeconomic, and cultural backgrounds, a parallel 3-arm assessor-blinded pragmatic multinational randomised controlled trial (RCT) with embedded exploratory trials and mechanistic studies will determine long-term effects of AMG and MLG versus TAU on addiction severity (primary endpoint: 1 year), recovery, and other outcomes. Embedded trials will examine immediate effects of AMG or MLG combined with individual components of TAU combined to determine the best combinations of interventions. Experimental studies will examine mechanisms using cognitive testing and brain imaging. With 600 participants in 7 countries randomised, the trial will have 80% power on the primary outcome. Patient representatives, health technology assessment (HTA) bodies, and interventionists have been involved from conception and will ensure feasibility and applicability of the intervention across Europe. DiscussionThis document describes the FALCO RCT, the main part of the FALCO project, which aims to reduce disease burden through innovative, effective, and affordable treatment, and will strengthen research and innovation expertise. Recommendations from FALCO will inform intervention delivery across Europe and beyond, leading to increased safety, effectiveness, and cost-effectiveness, and improved quality of life for individuals with SUD. Stakeholders will be involved in communicating findings across all European countries and regions and ensuring that findings are effectively implemented. Trial registrationClinicalTrials.gov, NCT07028983, registered 11th of June 2025. https://clinicaltrials.gov/study/NCT07028983

ObjectivesPeople impacted by the criminal-legal system face significant challenges to securing and sustaining permanent housing. This study was designed to assess housing outcomes of an integrated intervention that offered housing, medical, and behavioral health services to individuals with criminal-legal system involvement. MethodsAfter a baseline needs assessment, participants were linked to services and completed quarterly study visits for up to 12 months. We used descriptive statistics to assess frequency and multivariate logistic regression to assess correlates of being housed at last follow-up. ResultsBetween June 2019 and November 2023, 187 participants were enrolled in Project CHANGE from an area with high incarceration and overdose rates. At baseline, 43% of participants were unstably housed, 37% were homeless, and the remaining resided in a shelter or institution. At the time of last follow-up, 49 participants (26.2%) reported improved housing outcomes, and an additional 121 participants (64.7%) housing situation did not worsen. In multivariate models, individuals who were older (AOR 1.1; 95% CI 1.0-1.1), unstably housed at baseline (AOR 7.2; 95% CI 3.3-16.0), and enrolled in the study for longer (AOR 1.1; 95% CI 1.1-1.3) had higher odds of being housed at last follow-up, whereas those with high severity substance use had lower odds of being housed (AOR 0.3; 95% CI 0.1-0.6.) ConclusionsIn this comprehensive program, integrated housing/health services were time- and cost-intensive to deliver but led to positive housing outcomes. People involved in the criminal-legal system face unique barriers to housing, particularly when compounded by substance use.

Large language models (LLMs) are increasingly used for qualitative analysis in substance use research, yet their performance relative to human coders remains underexplored. This study compares ChatGPT-4.0 with human coders in identifying and describing the core innovation of NIH grants focused on reducing opioid overdose. A total of 118 NIH HEAL Initiative grant abstracts were independently coded by ChatGPT and humans to generate innovation descriptions, which were then evaluated by both human raters and ChatGPT for depth/detail and relevance/completeness using 5-point Likert scales. Identical instructions were used across all coding and evaluation stages. ChatGPT-generated descriptions were consistently rated higher than human-generated descriptions on both dimensions. Human evaluators rated ChatGPT outputs at an average of 4.47 for both depth/detail and relevance/completeness, compared to 3.33 and 3.24 for human outputs, respectively (F(1,176)=133.9, p<0.001). These findings suggest that LLMs, when carefully prompted, can enhance the efficiency and quality of qualitative research evaluation.

BackgroundCannabinoid hyperemesis syndrome (CHS) is characterized by episodes of severe nausea, vomiting, and abdominal pain among those with heavy cannabis use. We estimated differences between those reporting CHS symptoms and other daily and less frequent cannabis users on drug use, psychiatric problems, other health problems, antisocial behavior, and personality. MethodsThe National Firearms, Alcohol, Cannabis, and Suicide survey was administered to 7034 US adults in 2025. Survey items assessed substance use, common psychiatric symptoms, personality traits, and symptoms of CHS. ResultsThose with CHS symptoms reported the highest rates and greatest variety of drug use compared to others who used cannabis. Those with CHS symptoms reported higher rates of other drug use than those who used cannabis daily without CHS symptoms across a variety of drug classes, including opioids, hallucinogens, and sedatives, higher rates of drug overdoses, and greater use of all drug classes than those with less-than-daily cannabis use. Those with CHS symptoms also reported more depression, anxiety, sleep problems, chronic pain, antisocial behavior, intimate partner violence, and disinhibited personality traits than those who used daily (mean d = 0.58) and less frequently (mean d = 0.69) and those with no cannabis use in the past 12 months (mean d = 0.99). ConclusionsThose with CHS symptoms exhibit a variety of psychological and behavioral problems including higher rates of other drug use, psychiatric symptoms, antisocial behavior, and dysfunctional personality traits. Results highlight the importance of understanding and addressing the broader psychosocial challenges faced by people experiencing CHS symptoms. Highlights O_LICHS symptoms are linked to greater polysubstance use and overdose risk C_LIO_LICHS symptoms are associated with depression, anxiety, sleep, and pain problems C_LIO_LICHS tied to antisocial behavior and intimate partner violence C_LIO_LICHS shows disinhibited personality traits and low well-being C_LIO_LINational survey identifies high-risk psychosocial CHS profile C_LI

BackgroundRecreational cannabis legalization has expanded rapidly across US states. The regulatory approaches states adopt vary widely, with varying implications for public health. This study aimed to characterize heterogeneity in recreational cannabis laws (RCLs) across US states and to identify state-level characteristics associated with these regulatory models. MethodsWe conducted Latent Class Analysis (LCA) of state-year RCL provisions from 2013 to 2024 (n=612) to identify distinct RCL approaches. Descriptive analyses and exploratory multinomial regression analyses were used to examine correlations between state characteristics and RCL approaches from 2020 to 2024, when sufficient cross-state variation in RCL adoption was available. Eleven recreational cannabis policy provisions spanning governance, potency limits, consumption restrictions, access controls, taxation, marketing regulations, and driving prohibitions are primarily from the Alcohol Policy Information System. State-level characteristics included cannabis use prevalence, market conditions, medical cannabis history, political factors, demographic, and socioeconomic covariates obtained from multiple secondary data sources. ResultsWe identified four latent classes of state-year RCL provisions representing different regulatory approaches: No RCL, Pre-commercial, Full Access, and Dispensary Access. The No RCL corresponded to state-years without RCL. The Pre-commercial class represented state-years in early-stage legalization with a minimal regulated approach in terms of commercial infrastructure. The Full Access class was characterized by permitting on-site retail consumption and home delivery and restricting (but not prohibiting) public use. In contrast, the Dispensary Access class limited retail sales to off-site consumption only, prohibited public use, and imposed stricter market controls. Higher past-month cannabis use prevalence was associated with a greater likelihood of membership in the Full Access class (RRR = 1.78; 95% CI: 1.21-2.62), relative to No RCL. A longer duration since medical cannabis legalization was associated with a higher likelihood of membership in the Dispensary access class (RRR = 1.47; 95% CI: 1.02-2.12). Higher beer excise taxes were associated with a lower likelihood of membership in any RCL class relative to No RCL. ConclusionsFrom 2013 to 2024, US recreational cannabis regulations clustered into four distinct regulatory approaches, with two distinct commercial models: one permitting on-site retail consumption and home delivery, the other restricting sales to off-premises only and prohibiting public use. Higher cannabis use prevalence and longer medical cannabis history were associated with more access-oriented and more restrictive commercial approaches, respectively.

Alcohol use disorder (AUD) remains a major public health problem, with few effective medications and suboptimal adherence. L-type calcium channel blockers (LTCCBs) have genetic and preclinical support as potential treatments for AUD. We evaluated whether brain penetrant (BP)-LTCCBs are associated with reduced alcohol consumption by conducting two preregistered (https://osf.io/huawv) observational cohort studies using electronic health records (EHRs) from the US Department of Veterans Affairs (VA) and Kaiser Permanente Northern California (KPNC). New users of BP-LTCCBs (nifedipine or felodipine) were compared with new users of a non-BP-LTCCB (amlodipine) and with unexposed patients sampled from the same clinics, following a 180-day washout and requiring at least 60 days supply. Propensity score matching was conducted separately for BP-LTCCB versus unexposed, non-BP-LTCCB versus unexposed, and BP-versus non-BP-LTCCB. The primary outcome was change in drinks per week from the most recent pre-index screen to end of follow-up, estimated using difference-in-differences (DiD) models. Prespecified subgroup analyses were conducted by AUD diagnosis, baseline drinking level, and sex. Across both health systems, BP-LTCCB initiation was not associated with greater reductions in drinks per week than either comparator, with broadly consistent findings across all subgroups. In two large, preregistered EHR-based cohorts with rigorous confounding control, BP-LTCCBs were not associated with reduced drinking relative to comparators. Despite compelling genetic and preclinical evidence, these results do not support repurposing BP-LTCCBs for AUD, highlighting the need to prioritize alternative pharmacologic targets, potentially within etiologically informed subgroups.

ObjectiveAs cannabis use has increased in the United States, so has cannabinoid hyperemesis syndrome (CHS), a disorder characterized by severe nausea, vomiting, and abdominal pain among heavy cannabis users. We previously showed that CHS symptoms are associated with several behavioral and psychological characteristics linked to psychosocial impairment. We examined links between CHS symptoms and suicidal thoughts, behaviors, and proximal suicide risk factors. MethodsWe used data from the National Firearms, Alcohol, Cannabis, and Suicide survey, a nationally representative survey of 7,034 US adults. Items assessed symptoms of CHS and suicidal thoughts and behaviors. Comparisons focused on: those with daily cannabis use and CHS symptoms (n = 191), those with daily cannabis use without CHS symptoms (n = 882), those with past year cannabis use but not daily use (n = 1288), and those without past year cannabis use (n = 4673). ResultsThose with CHS symptoms reported the highest prevalence of suicidal thoughts and behaviors with most lifetime rates being significantly higher than those with daily cannabis use without CHS symptoms. Those with CHS symptoms also reported higher mean-levels of thoughts and feelings associated with suicide (i.e., perceived burdensomeness, thwarted belongingness, defeat, entrapment) than all the other groups. ConclusionsThose with CHS symptoms reported especially high rates of suicidal thoughts, behaviors, and attempts even when compared to others with daily cannabis use. People with CHS symptoms appear to be at high risk of suicide, possibly related to distress from their gastrointestinal symptoms and psychiatric, substance use, and medical comorbidities.

Objective: Minimum unit pricing (MUP) aims to reduce use of cheap, high strength alcoholic beverages that drive harm, yet concerns remain about inequitable effects for structurally vulnerable groups. As part of the Costs, Harms, Expenditures and Alcohol Prices (CHEAP) study, we linked individual-level, product-specific alcohol consumption data from a customized survey with provincial retail price data to estimate prices per standard drink (PPSD) and examine their association with alcohol-related outcomes across sociodemographic groups. Method: A cross-sectional survey of past-week drinkers in British Columbia, Canada, was linked to provincial product-level alcohol sales data. The population weighted sample included 1,217 adults aged [&ge;] 19 years (716 men; mean age 49.34, SD 16.98). Participants reported product-specific consumption, which was matched to retail prices to calculate individual-level PPSD. Survey weighted quasibinomial models then examined associations between PPSD and three outcomes: (1) causing harm to self or others in the past year, (2) scoring [&ge;] 8 on the Alcohol Use Disorder Identification Test, and (3) consuming [&ge;] 15 standard drinks per week. Analyses were stratified by income, education, subjective social status, and race/ethnicity. Results: Lower price per standard drink was associated with higher odds of harm (OR 3.05, 95% CI 1.25-7.40) and scoring [&ge;] 8 on the AUDIT (OR 2.34, 95% CI 1.37-3.99). Associations were stronger among structurally disadvantaged groups, including low-income respondents and Indigenous participants. Conclusions: Lower alcohol affordability is linked to risky alcohol use, with the strongest effects among structurally disadvantaged groups. MUP would reduce this risk and promote health equity.

Despite decades of clinical implementation of medications for opioid use disorder (OUD), overdose mortality rates remain high, underscoring a critical gap in treatments that target brain mechanisms driving addiction. Mindfulness-Oriented Recovery Enhancement (MORE) has demonstrated efficacy in reducing opioid use and craving, hypothetically by restructuring the salience of drug and natural rewards. Yet, to date, MOREs neurobiological mechanisms remain unclear. In this first functional magnetic resonance imaging (fMRI) randomized controlled trial (RCT) of MORE for OUD (NCT04112186), we tested whether compared with an active psychoeducational supportive therapy (PST) control group, MORE rebalanced neural responses to drug and natural reward cues in inpatients with OUD receiving standard of care including medications. Compared with PST, eight weeks of MORE significantly reduced drug-biased activity in the dorsolateral prefrontal cortex (dlPFC) and posterior regions of the default mode network including the precuneus during downregulation of responses to drug cues relative to upregulation of responses to natural reward cues (even when controlling for passive cue viewing). The shift from drug to natural reward responses in the lateral and ventromedial PFC was associated with lower cue-induced craving exclusively in the MORE group. MORE also reduced medial PFC synchronization to naturalistic drug-related movie scenes and significantly extended abstinence duration at follow-up ([~]4 months post-treatment) relative to PST. Together, this neuroimaging RCT demonstrates that MORE normalizes function in PFC nodes of the reward, salience, and control systems, positioning MORE as a biologically-grounded adjunct to pharmacotherapy for OUD.

BackgroundTraumatic events, such as terror attacks and war, are expected to impact mental health. These potential effects can be explored by assessing the mental health of the general population of Israel, from before the events of October 7, 2023 and over the course of the Swords of Iron war. MethodsGeneral population data were collected from Jewish adults in Israel before October 7 (April 2022), after October 7 (December 2023), and over the course of the ongoing war (March 2024, June 2024, February 2025), in a series of repeated cross-sectional samples with longitudinal data on a subset of the respondents. Among a subset of the sample including individuals who were surveyed in April 2022 and at least one follow-up time point (N=1,368), we used regression analysis to model trajectories over time in prevalence of problematic non-medical use of alcohol, tobacco, cannabis, sedatives, prescription stimulants, and prescription opioid painkillers; problematic use of internet, social media, electronic gaming, gambling, pornography, and compulsive sexual behavior; and post-traumatic stress disorder (PTSD), depression, and anxiety. Trajectories were modeled overall and moderation analysis was used to determine if trajectories differed by gender or age. ResultsDifferent patterns were observed by outcome. Different trajectories were observed before and after December 2023, suggesting that the events of October 7th and the early war may have been a key transition point, for problematic use of alcohol, tobacco, sedatives, opioid painkillers, gambling, sexual behaviors, internet and PTSD. Smooth changes over time were observed for problematic use of gaming and social media, and anxiety and depression. No changes over time were observed for problematic use of cannabis, stimulants, and pornography. Many outcomes showed different trajectories by gender and age. ConclusionsFindings suggest possible effects of ongoing trauma and war and suggest that outcome-specific and group-specific strategies may be warranted. Monitoring the prevalence of addictions and other common mental health issues in the general population during and after nationally traumatic events is important to understand the evolving mental health of the population and provide information and resources for potential interventions. Awareness of the potentially harmful effects of such life events, as well as the consequences of maladaptive coping styles on health and well-being, should be increased.

BackgroundArticle 5.3 of the WHO Framework Convention on Tobacco Control requires Parties to protect policies from tobacco industry interference, yet implementation remains weak internationally. Aotearoa New Zealands (Aotearoa NZ) is seen as a leader in tobacco control, yet little is known about its implementation of Article 5.3 protections. This study examines these protections as well as existing transparency measures in light of the 2024 repeal of world-leading tobacco control policies. MethodsInterviews with current and former: public health experts, politicians, officials and political journalists, and analysis of key texts. ResultsAotearoa NZs Article 5.3 implementation and scope is constrained, leaving invisible and exploitable paths of influence. Public health experts argued protections have been neglected from the start. Politicians were unaware of Article 5.3 obligations, and reported limited guidance on industry interactions. These gaps are compounded by non-existent lobbying laws and ill-equipped transparency measures. ConclusionDespite the countrys reputation for strong tobacco controls, structural policy and implementation failures leave Aotearoa NZs health policies vulnerable to industry interference. Aotearoa NZ and other Parties should consider institutionally embedding comprehensive Article 5.3 protections to safeguard policy decisions from tobacco industry influence. WHAT THIS PAPER ADDSO_ST_ABSWhat is already known on this topicC_ST_ABSTobacco industry interference remains the biggest barrier to tobacco control policies, with evidence consistently identifying gaps in Parties implementation of Framework Convention on Tobacco Control Article 5.3 protections. Parties often rely on pre-existing measures such as lobbying laws. What this study addsThis is the first study examing Aotearoa NZs implementation of Article 5.3. It shows that despite its reputation as a tobacco control leader, implementation is severely limited and pre-existing measures are inadequate, enabling a system in which industry interference can go on unseen. How this study might affect research, practice or policyBy identifying how structural policy gaps enable industry interference, this study highlights the need for comprehensive institutional embedding of Article 5.3 protections across government, and consideration of its codification into law.

Alcohol Use Disorder (AUD) is a multifactorial condition with severe individual and societal impacts. Extending our 2024 study, this work examines lifestyle, background, and family history determinants of AUD using an expanded dataset from the All of Us Research Program. The updated analysis includes approximately 2.5 times more participants than the prior study, enabling improved statistical power and evaluation of result stability over time. Using interpretable machine learning models and statistical analyses, we identified annual income, residential stability, recreational drug use, sex/gender, marital status, education, and family history as key contributors to AUD risk. Annual income remained the most influential predictor across both datasets, while other feature rankings showed modest shifts. Family history factors continued to demonstrate non-linear effects, with close relatives AUD status remaining influential despite differences between statistical association and predictive importance. In predicting AUD versus non-AUD status, Random forest models achieved the highest classification accuracy (81%), consistent with 2024 results but with improved precision for identifying AUD cases. Overall, the findings confirm the robustness of previously identified AUD determinants and underscore the need for coordinated, multi-level prevention strategies addressing behavioral, familial, and structural factors contributing to AUD.

BackgroundTheta-band oscillation is integral to fronto-parietal connectivity in the executive control network and its top-down regulation on subcortical areas. External frontoparietal synchronization using theta-frequency transcranial alternating current (tACS) is a technology to potentially engage this network. In this pre-registered, triple-blind, sham-controlled trial (NCT03907644), we tested this intervention targeting the right frontoparietal network in people with opioid use disorder (OUD) to measure network engagement and behavioral outcomes. MethodSixty male participants with OUD were randomized to receive 20 minutes of active or sham 6 Hz tACS (HD electrodes over F4 and P4). Structural, resting-state, task-based fMRI drug cue reactivity, and repeated cue-induced craving assessments were collected immediately before and after stimulation. Pre-registered outcome measures were analyzed using timexgroup interaction models to examine (1) modulation of drug cue-related brain activity, (2) changes in craving, (3) alterations in functional connectivity, and (4) relationship between electric field, neural responses, and craving behavior. Results(1) A significant Time x Group interaction revealed decreased post-stimulation opioid cue-related activity in the active group relative to sham, involving key nodes in reward processing (ventral striatum, amygdala and ventral tegmental area) (FWE corrected =0.05) (2) subjective craving did not differ significantly between groups (3) Group by time generalized psychophysiological interaction analyses showed increased right frontoparietal network engagement ({beta}=2.63, p=0.0308) following stimulation, and increased top-down inhibitory regulation of frontoparietal network on right ventral striatum ({beta}=1.99, p=0.037) and left medial amygdala ({beta}=1.97, p=0.039) (4) Electric field strength in the right frontal/parietal node predicted frontoparietal network engagement in the active group (r=0.43, p=0.02). ConclusionTogether, these findings demonstrate that theta-band frontoparietal tACS can modulate activity and task-dependent coupling within cortical-subcortical circuits in OUD, supporting network-targeted neuromodulation as a potential intervention for addiction. Significance StatementAddiction is linked to imbalances in cortico-subcortical brain circuits that control reward processing and craving. This study tested whether a non-invasive brain stimulation method-- theta-band transcranial alternating current stimulation (tACS)--can rebalance these circuits in people with opioid use disorder. Using advanced brain imaging, we found that tACS strengthened communication within frontoparietal brain regions involved in self-control while reducing their connections with reward and emotion centers. These brain changes were linked to reduced craving responses to drug cues. Our results demonstrate that dual-site, network-targeted tACS modulates neural activity and task-dependent engagement of brain circuits during drug cue reactivity in addiction, supporting its potential as a novel therapeutic approach.

Background At present, there are no approved pharmacological treatments for people at clinical high risk for psychosis (CHR-P). We sought to assess the acceptability of cannabidiol (CBD): a promising candidate treatment for this population. Methods CHR-P individuals completed a survey which assessed their views on the acceptability of CBD, its expected effectiveness and side effects, and on formulation preferences. Results The sample comprised 55 CHR-P individuals (24.3 years and 69% female). Most (91%) were familiar with CBD, and had previously used cannabis (64%), and around half (42%) had tried over-the-counter CBD. 75% were willing to take CBD as an intervention for mental health problems. Most participants anticipated fewer side effects with CBD than with existing medications, and preferred tablet or capsule formulations over liquids. Discussion CBD is perceived as a highly acceptable treatment among CHR-P individuals.